Federal authorities weigh legal action against Hims following brief weight loss pill launch
Federal officials are weighing fines against Hims for offering a copy of Novo Nordisk's Wegovy. The FDA referred the case to the DOJ despite Hims' retreat.
Insights:
The U.S. Food and Drug Administration (FDA) has referred the telehealth company Hims & Hers Health, Inc. to the Department of Justice (DOJ) regarding the firm's intended sale of a compounded version of Wegovy, a weight-loss drug manufactured by Novo Nordisk A/S . This referral, occurring as of February 13, 2026, marks a significant development in the oversight of pharmaceutical distribution within the US 
US. The action follows the public announcement by Hims of its plan to offer the compounded medication, which was followed by a rapid retreat from the proposal amid regulatory scrutiny.
US. The action follows the public announcement by Hims of its plan to offer the compounded medication, which was followed by a rapid retreat from the proposal amid regulatory scrutiny.
